RASA2 and cutaneous melanoma: Somatic mutations that activate the MAPK pathway in cutaneous melanoma include oncogenic mutations at specific hotspots in NRAS and BRAF (2, 3) and tumor suppressor mutations in negative regulators, such as RASA2 and NF1 (4, 5).